GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Arjo AB (STU:A39) » Definitions » Debt-to-EBITDA

Arjo AB (STU:A39) Debt-to-EBITDA : 0.59 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Arjo AB Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Arjo AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €34.1 Mil. Arjo AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €71.4 Mil. Arjo AB's annualized EBITDA for the quarter that ended in Mar. 2024 was €178.5 Mil. Arjo AB's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 0.59.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Arjo AB's Debt-to-EBITDA or its related term are showing as below:

STU:A39' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.31   Med: 2.8   Max: 5.17
Current: 0.6

During the past 11 years, the highest Debt-to-EBITDA Ratio of Arjo AB was 5.17. The lowest was 0.31. And the median was 2.80.

STU:A39's Debt-to-EBITDA is ranked better than
72% of 75 companies
in the Medical Distribution industry
Industry Median: 2 vs STU:A39: 0.60

Arjo AB Debt-to-EBITDA Historical Data

The historical data trend for Arjo AB's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arjo AB Debt-to-EBITDA Chart

Arjo AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.71 3.39 2.68 3.72 2.80

Arjo AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.61 0.61 0.58 2.85 0.59

Competitive Comparison of Arjo AB's Debt-to-EBITDA

For the Medical Distribution subindustry, Arjo AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arjo AB's Debt-to-EBITDA Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Arjo AB's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Arjo AB's Debt-to-EBITDA falls into.



Arjo AB Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Arjo AB's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(205.524 + 284.909) / 175.308
=2.80

Arjo AB's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(34.109 + 71.399) / 178.5
=0.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Arjo AB  (STU:A39) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Arjo AB Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Arjo AB's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Arjo AB (STU:A39) Business Description

Traded in Other Exchanges
Address
Hans Michelsensgatan 10, Malmo, SWE, SE-211 20
Arjo AB is a supplier of medical devices, services, and solutions in Sweden. It serves its services to private and public institutions with acute care and long-term care. The company's offering includes products and solutions for patient handling, hygiene, disinfection, medical beds, therapeutic surfaces, venous thromboembolism (VTE) prevention and diagnostics. It also offers services such as training in connection with product sales. Geographically, it derives a majority of revenue from Western Europe and also has a presence in North America; and the Rest of the World.

Arjo AB (STU:A39) Headlines

No Headlines